Finanzwire Finanzwire
Basculer en Français
10336 Companies
214545 Keywords
144372 Articles
113640 Press releases
Headlines Articles Press releases Clairvoyant Therapeutics Remove
  1. Home
  2. Companies
  3. Clairvoyant Therapeutics
Finanzwire
Basculer en Français
Headlines Articles Press releases

News

  • BRIEF

    published on 04/03/2024 at 14:05, 2 years ago

    Clairvoyant Therapeutics Advances Psilocybin Clinical Trial for Alcohol Use Disorder

    Clinical Trial Clairvoyant Therapeutics Psilocybin Treatment Alcohol Use Disorder Regulatory Pathway
  • PRESS RELEASE

    published on 04/03/2024 at 14:00, 2 years ago

    Psilocybin Clinical Trial Sponsored by Clairvoyant Therapeutics Reaches 90% Randomization

    Clairvoyant Therapeutics aims to commercialize psilocybin treatment for alcohol use disorder by 2025. Company's trial progressing well, expecting results in 2024 & financing round underway
    Commercialization Clinical Trial Clairvoyant Therapeutics Psilocybin Treatment Alcohol Use Disorder
    Logo of Clairvoyant Therapeutics
  • PRESS RELEASE

    published on 11/29/2023 at 13:00, 2 years 5 months ago

    Clairvoyant Surpasses 50 Per Cent Randomization in its Phase 2b Psilocybin Therapy Trial for Alcohol Use Disorder

    Logo of Clairvoyant Therapeutics
  • PRESS RELEASE

    published on 03/20/2023 at 12:00, 3 years 1 month ago

    First Patient Dosed in Europe in Clairvoyant’s Phase 2b Clinical Trial Exploring Psilocybin Therapy as a Treatment for Alcohol Use Disorder

    Logo of Clairvoyant Therapeutics
Accesswire
  • Published on 05/02/2026 at 01:30, 1 hour 35 minutes ago

    Uraniumx Reports Strong Financial Position Ahead of Spring Drill Program

  • Published on 05/02/2026 at 00:50, 2 hours 15 minutes ago

    CoTec Announces Annual Stock Option, Restricted Share Unit And Deferred Share Unit Grants

  • Published on 05/02/2026 at 00:00, 3 hours 5 minutes ago

    Redwood AI Announces Enhanced AI Models, Increasing Evaluated Chemical Reactions Following Preliminary Results from UBC Collaboration

  • Published on 05/02/2026 at 00:00, 3 hours 5 minutes ago

    Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling Studies

  • Published on 05/01/2026 at 22:30, 4 hours 35 minutes ago

    Nextech3D.ai Appoints New Independent Auditor

View all ACCESSWIRE
EQS Group
  • Published on 05/01/2026 at 19:23, 7 hours 42 minutes ago

    Fuller, Smith & Turner PLC: Transaction in own shares

  • Published on 05/01/2026 at 18:40, 8 hours 25 minutes ago

    Holding(s) in Company

  • Published on 05/01/2026 at 17:47, 9 hours 18 minutes ago

    Key Figures 30.04.2026

  • Published on 05/01/2026 at 17:45, 9 hours 20 minutes ago

    Burkhalter Group acquires Progressio Holding GmbH and anplaq ag, Tamins (GR)

  • Published on 05/01/2026 at 17:21, 9 hours 44 minutes ago

    Fuller, Smith & Turner PLC: Total Voting Rights and Treasury Shares

View all EQS
Les Echos
  • Published on 04/30/2026 at 20:00, 1 day 7 hours ago

    AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue

  • Published on 04/30/2026 at 19:16, 1 day 7 hours ago

    AXA announces the results of its Shareholders' Meeting

  • Published on 04/30/2026 at 19:00, 1 day 8 hours ago

    Capital increase through exercise of subscription rights

  • Published on 04/30/2026 at 18:10, 1 day 8 hours ago

    Minutes of the Combined General Meeting held on April 30, 2026

  • Published on 04/30/2026 at 18:00, 1 day 9 hours ago

    TF1 Q1 2026 results - Press release

View all LES ECHOS COMFI WIRE

With finanzwire.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

Finanzwire

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

© 2026 Finanzwire

Contact Authors Cookies policy Terms and conditions Privacy policy